At GSK, we are committed to playing our part in addressing the global healthcare challenges of this century.
In October 2011 we further demonstrated our commitment to this fight by joining WIPO Re:Search, a new open innovation platform with the aim of helping to accelerate the development of new and better treatments against neglected tropical diseases such as dengue, rabies and Chagas disease as well as malaria and tuberculosis.
WIPO Re:Search is a collaboration of private and public sector organisations sponsored by the World Intellectual Property Organization (WIPO) in collaboration with BIO Ventures for Global Health (BVGH).
This collaboration builds on the Pool for Open Innovation against Neglected Tropical Diseases which was established in February 2009 with patents from GSK and Alnylam Pharmaceuticals. This IP pool was the first to effort to ensure intellectual property did not act as a barrier to research for neglected tropical diseases.
A coordinated approach to developing new treatments for these diseases, which disproportionately affect the least developed countries, is needed. To successfully meet the challenges in global health drug development, new partnerships and new approaches must be formed between organisations with a new mindset - one which is more innovative, flexible, and willing to take risks. GSK is committed to being actively involved.
Find out more about WIPO Re:Search and about the Pool for Open Innovation against Neglected Tropical Diseases on their websites.
Building the best product pipeline in the industry
Find out more about our pipeline